Abstract:The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of acute cardiac transplant rejection or cardiac allograft vasculopathy. In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 (CXCL9) antibody (Ab), CXCL10 Ab and FTY720 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation murine model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 mice at day 28 after skin transplantation. The mice were divided into four groups: i) Control (normal saline), ii) CXCL9 Ab and CXCL10 Ab [150 μg; once daily (qd); intraperitoneal (ip)], iii) FTY720 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of interleukin (IL)-2 was significantly lower and the levels of IL-10 and transforming growth factor-β (TGF-β) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of IL-2 and interferon-γ (IFN-γ) were significantly lower (P<0.001) and the concentration of IL-10 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with CXCL9 Ab and CXCL10 Ab or FTY720 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of CXCL9 Ab, CXCL10 Ab and FTY720 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.

[Study the Mechanisms and Inducing Transplantation Immune Tolerance of FTY720].

The effects of FTY720 on lymphocytes and monocytes in mouse intestinal transplantation

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

Preventive Effect of FTY720 on Acute Rejection of Islet Allograft Transplantation in Mice

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus.

Immunomodulatory drug FTY720 induces regulatory CD4+CD25 + T cells in vitro

The Protective Role of FTY720 in Promoting Survival of Allograft Fat in Mice.

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Long‐term Effect of FTY720 on Lymphocyte Count and Islet Allograft Survival in Mice

Adoptive Transfer of FTY720-treated Immature BMDCs Significantly Prolonged Cardiac Allograft Survival.

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

An Immunotherapeutic Strategy for Prolonging Graft Survival in Mice.

SYNERGISTIC TOLERANCE BY ADOPTIVE TRANSFER OF TOLEROGENIC DENDRITIC CELLS AND T REGULATORY CELLS:

Immunotherapeutic strategy based on anti-OX40L and low dose of IL-2 to prolong graft survival in sensitized mice by inducing the generation of CD4+ and CD8+ Tregs

Effect and Mechanisms of Transplantation Tolerance Induced by Donor Natural Killer T Cells(NKT) Infused Intravenously

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients.

Transforming Growth Factor Β1 and Fas Ligand Synergistically Enhance Immune Tolerance in Dendritic Cells in Liver Transplantation.

Donor specific transfusion of splenocytes combined with delayed low dosage tacrolimus administration induce immune tolerance in allogene rat heart transplantation

LF 15-0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model.